Your browser doesn't support javascript.
loading
Kidney Transplantation Results in Very Highly Sensitized Patients Included in a Virtual Crossmatch Program: Analysis of Kidney Pairs.
Mazuecos, A; Alvarez, A; Nieto, A; Gentil, M A; Cabello, M; Rodriguez-Benot, A; Gracia, C; Gonzalez, F; Castro, P; Alonso, M.
Afiliação
  • Mazuecos A; Nephrology Department, Hospital Puerta del Mar, Cadiz, Spain. Electronic address: mauxiliadora.mazuecos.sspa@juntadeandalucia.es.
  • Alvarez A; Coordinacion de Trasplantes de Andalucia, Sevilla, Spain.
  • Nieto A; Immunology Department, Hospital Puerta del Mar, Cadiz, Spain.
  • Gentil MA; Nephrology Department, Hospital Virgen del Rocio, Sevilla, Spain.
  • Cabello M; Nephrology Department, Hospital Regional de Malaga, Malaga, Spain.
  • Rodriguez-Benot A; Nephrology Department, Hospital Reina Sofia, Cordoba, Spain.
  • Gracia C; Nephrology Department, Hospital Virgen de las Nieves, Granada, Spain.
  • Gonzalez F; Immunology Department, Hospital Virgen del Rocio, Sevilla, Spain.
  • Castro P; Coordinacion de Trasplantes de Andalucia, Sevilla, Spain.
  • Alonso M; Coordinacion de Trasplantes de Andalucia, Sevilla, Spain.
Transplant Proc ; 48(9): 2899-2902, 2016 Nov.
Article em En | MEDLINE | ID: mdl-27932102
BACKGROUND: Kidney transplantation in highly-sensitized (HS) patients can improve with organ-exchange strategies based on virtual crossmatch (V-XM). Experience in very-HS patients is limited. METHODS: In June 2012, Andalusia started a V-XM protocol for very-HS patients (calculated panel reactive antibodies ≥95%). After organ allocation a cytotoxic-XM performed immediately before transplantation had to be negative for surgery to proceed. We analyzed results up until December 2015. Whenever possible we also compared the course of the recipient (non-HS) of the other kidney from the same donor. RESULTS: Of the 57 grafts, 52 kidney transplantations were performed (the pretransplantation cytotoxic-XM was positive in 5; predictive value 91.3%). Five patients (9.6%) experienced acute rejection (4 antibody-mediated rejections [AMRs]; 7.6%). Donor-specific antibodies developed in 10 patients. No patient died. One-year graft survival was 98%. We compared the course of the non-HS recipient of the other kidney, excluding cases with no pair (n = 5), pairs who were children recipients (n = 3), pancreas-kidney recipients (n = 5), or pairs already included in the V-XM protocol (n = 4). Finally, 35 pairs were studied. More HS-patients developed donor-specific antibodies (P = .016). No significant differences were seen in acute rejection, but AMR was more common (P = .057). No deaths occurred in either group, and there were no differences in graft survival or renal function. CONCLUSIONS: Although a few patients still developed AMR, our V-XM based protocol with a final pretransplantation cytotoxic-XM achieved very satisfactory results. Although the number of patients was limited, the initial survival of these high-risk recipients was comparable to the controls.
Assuntos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Tipagem e Reações Cruzadas Sanguíneas / Transplante de Rim / Sobrevivência de Enxerto Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplant Proc Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Tipagem e Reações Cruzadas Sanguíneas / Transplante de Rim / Sobrevivência de Enxerto Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplant Proc Ano de publicação: 2016 Tipo de documento: Article